If you have been reading about lipolysis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-28. Numbers and descriptions here follow the published literature rather than marketing material.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
== Biography == Leonard Thompson was born on Pickering Street near the Beaches neighbourhood of Toronto on 17 July 1908, to parents Harold and Florence Thompson. He was diagnosed with diabetes mellitus, and was first treated at the Hospital for Sick Children before being transferred to the care of physicians Andrew Almon Fletcher, Duncan Archibald Graham, and Walter Ruggles Campbell. Thompson received his first injection in Toronto, Ontario, on 11 January 1922, at 13 years of age. Thompson's first dose had an apparent impurity which caused an allergic reaction. A refined process was quickly developed to concentrate the pancreatic extract. Twelve days later, on 23 January, he began a two-week series of daily injections that rapidly improved his health, allowing him to live until dying of bronchopneumonia at age 26. Until insulin was made clinically available, a diagnosis of diabetes was a death sentence, more or less quickly (usually within months, and frequently within weeks or days).
=== Josh Thomas and Lachlan Keeffe === Lachlan Keeffe (drafted to Collingwood in 2008) and Josh Thomas (drafted to Collingwood in 2009) are the most recent players to breach the anti-doping code. They both tested positive for clenbuterol which led to a 2-year ban as well as a $50,000 fine. The banned substance was detected in their systems after taking illicit drugs during a night out. Both players were banned from playing AFL for 2 years and were delisted by the Collingwood Football Club, before being redrafted by Collingwood in the 2016 Rookie Draft.
=== FastPP === In fast parallel proteolysis the researcher adds a thermostable protease (thermolysin) and takes out samples in parallel upon heating in a thermal gradient cycler. Optionally, for instance for proteins expressed at low levels, a western blot is then run to determine at what temperature a protein becomes degraded. For pure or highly enriched proteins, direct SDS-PAGE detection is possible facilitating Commassie-fluorescence based direct quantification. FastPP exploits that proteins become increasingly susceptible to proteolysis when unfolded and that thermolysin cleaves at hydrophobic residues which are typically found in the core of proteins. To reduce the workload, western blots could be replaced by SDS-PAGE gel polyhistidine-tag staining, provided that the protein has such a tag and is expressed in adequate amounts. FastPP can be used on unpurified, complex mixtures of proteins and proteins fused with other proteins, such as GST or GFP, as long as the sequence that is the target of the western blot, e.g., His-tag, is directly linked to the protein of interest. However, commercially available thermolysin is dependent on calcium ions for activity and denatures itself just above 85 degrees Celsius. So calcium must be present and calcium chelators absent in the buffer - other compounds that interfere with the function (such as high concentrations of detergents) of the protease could also be problematic. FASTpp has also been used to monitor binding-coupled folding of intrinsically disordered proteins (IDPs).
Sources: en.wikipedia.org
Spinoff is a NASA publication featuring technology made available to the public. Since 1976, NASA has featured an average of 50 technologies each year in the annual publication, and Spinoff maintains a searchable database of these technologies. When products first spun off from space research, NASA presented a black and white report in 1973, titled the "Technology Utilization Program Report". Because of interest in the reports, NASA decided to create the annual publications in color. Spinoff was first published in 1976, and since then, NASA has distributed free copies to universities, the media, inventors and the general public. Spinoff describes how NASA works with various industries and small businesses to bring new technology to the public. As of 2016, there were over 1,920 Spinoff products in the database dating back to 1976.
An open border is the deregulation and/or lack of regulation of the movement of persons between nations and jurisdictions; this does not apply to trade or movement between privately owned land areas. Most nations have open borders for travel within their nation of travel, though more authoritarian states may limit the freedom of internal movement of its citizens, as for example in the former USSR. However, only a handful of nations have deregulated open borders with other nations, an example of this being European countries under the Schengen Agreement or the open Belarus-Russia border. Open borders used to be very common among all nations, however this became less common after the First World War, which led to the regulation of open borders, making them less common and no longer feasible for most industrialised nations. Open borders are the norm for borders between subdivisions within the boundaries of sovereign states. However, some countries do maintain internal border controls (for example between the People's Republic of China mainland and the special administrative regions of Hong Kong and Macau; or between the American mainland, the unincorporated territories other than Puerto Rico, and Hawaii. Open borders are also usual between member states of federations, however, movement between member states is controlled in exceptional circumstances. Federations, confederations, and similar multinational unions typically maintain external border controls through a collective border control system.
peptide map A characteristic fractionation pattern produced by a particular polypeptide or protein when it is subjected to partial hydrolysis in vitro and the resulting peptide chains are separated by chromatography and/or electrophoresis.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.